Essa Pharma Inc Reports Results For The Quarter Ended September 30: Earnings Summary

ESSA Pharma

17/12/2024 13:13

* ESSA Pharma Inc  EPIX.OQ  reported a quarterly adjusted
loss
of 14 cents​​ per share for the quarter ended September 30,
lower than the same quarter last year, when the company reported
EPS of -12 cents.  The mean expectation of five analysts for the
quarter was for a loss of 19 cents per share. Wall Street
expected results to range from -25 cents to -15 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * ESSA Pharma Inc's reported EPS for the quarter was a loss
of 14
cents​.
    * The company reported a quarterly loss of $6.36 million.
    * ESSA Pharma Inc shares had fallen by 73.1% this
quarter and
lost 75.3% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 7.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"

Wall Street's median 12-month price target for ESSA Pharma Inc
is $2.00 
This summary was machine generated from LSEG data December 17 at
01:12 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.19          -0.14          Beat
 Jun. 30 2024      -0.25          -0.16          Beat
 Mar. 31 2024      -0.19          -0.20          Missed
 Dec. 31 2023      -0.17          -0.14          Beat